CD8A and Familial prostate cancer: At the same time, treatment with ipilimumab has been shown to upregulate expression of PD-L1 and V-domain immnunoglobulin suppressor of T-cell activation in CD4+ T cells, CD8+ T cells, and CD68+ macrophages within prostate cancer tissue samples compared to untreated samples [76].